Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase II trial of combined chemoradiation [gemcitabine + radiotherapy] with epidermal growth factor receptor (EGFR) antagonist cetuximab versus combined chemoradiation with EGFR antagonist cetuximab and sequential cetuximab for patients with locally advanced pancreatic adenocarcinoma

Next Previous
Trial Profile

Randomized phase II trial of combined chemoradiation [gemcitabine + radiotherapy] with epidermal growth factor receptor (EGFR) antagonist cetuximab versus combined chemoradiation with EGFR antagonist cetuximab and sequential cetuximab for patients with locally advanced pancreatic adenocarcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PARC

Most Recent Events

  • 13 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top